Terns Pharmaceuticals, Inc. Operating CF/Net income

Operating CF/Net income of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating CF/Net income growth rates and interactive chart. Calculated as operating cash flow divided by net income to common shareholders. Also called income quality ratio. A ratio of greater than 1.0 usually indicates high-quality income, while a ratio of less than 1.0 indicates low-quality.


Highlights and Quick Summary

  • Operating CF/Net income for the quarter ending March 31, 2022 was 0.97 (a 28.97% increase compared to previous quarter)
  • Year-over-year quarterly Operating CF/Net income increased by 18.37%
  • Annual Operating CF/Net income for 2021 was 0.83 (a -17.89% decrease from previous year)
  • Annual Operating CF/Net income for 2020 was 1.02 (a 5.22% increase from previous year)
  • Annual Operating CF/Net income for 2019 was 0.97 (a -5.4% decrease from previous year)
  • Twelve month Operating CF/Net income ending March 31, 2022 was 0.81 (a -3.27% decrease compared to previous quarter)
  • Twelve month trailing Operating CF/Net income decreased by -0.33% year-over-year
Trailing Operating CF/Net income for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
0.81 0.83 0.84 0.81
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating CF/Net income of Terns Pharmaceuticals, Inc.

Most recent Operating CF/Net incomeof TERN including historical data for past 10 years.

Interactive Chart of Operating CF/Net income of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Operating CF/Net income for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.97
2021 0.75 0.68 0.82 1.07 0.83
2020 0.74 0.55 0.91 0.81 1.02
2019 6.77 0.97
2018 1.02

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.